Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the supplementary application of the lactulose oral solution, facilitating a change in the marketing authorization holder. This approval follows an agreement with Beijing Minkangbaicao Medicine Technology Co., Ltd. for a technology transfer, including rights to marketing and sales. This strategic move is set to enhance Xinhua Pharmaceutical’s market presence in the pharmaceutical industry.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.
